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ABSTRACT
Peripheral blood stem cells (PBSC) have been increasingly used in the matched unrelated donor (MUD) trans-
plant setting, but the impact of CD341 cell dose on outcomes in this setting have not been well characterized.
We analyzed 181 consecutive patients who underwentMUD-PBSC transplantation at the City of Hope between
August 2000 to December 2004. Patients were conditioned with either full-intensity regimen or reduced-inten-
sity regimen. There was a significant inverse relationship between higher CD341 cell dose and faster neutrophil
engraftment (r 5 20.16, P 5 .035). By univariate analysis, a CD341 cell dose $4.2  106/kg (above the lowest
quartile) was associated with significantly lower relapse risk (hazard ratio [HR] 5 0.67, P 5 .0126), with a trend
for corresponding improvement for disease-free survival (HR50.84,P5 .12) but not overall survival (HR5 0.91,
P 5 .46). The impact of the CD341 cell dose remained significant in multivariate analysis. The higher CD341
cell dose was significantly associated with faster recovery of absolute lymphocyte counts on day 130 posttrans-
plant. Subset analysis demonstrated that the higher CD341 cell dose was associated with (1) greater reduction
in relapse in myeloid malignancies than that in lymphoid malignancies, (2) greater reduction in reduced-inten-
sity conditioning than in full-intensity conditioning, (3) greater reduction in relapse when there is a inhibitory
killer-cell immunoglobulin-like receptor ligand (iKIRL)-mismatch in the gravft-versus-host (GVH) direction,
and (4) greater reduction in relapse when there is a lack of iKIRL, suggesting that the protective effect of
CD341 cell dose against relapse may be immune-mediated, possibly through NK cell recovery.
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Outcome after allogeneic hematopoietic stem cell
transplants (HCT) is strongly influenced by many
factors beyond the control of the treating physician,
including patient age, disease status, cytomegalovirus
(CMV) serology, and donor type. Other factors that
can be modified, including the conditioning regimen,graft-versus-host disease (GVHD) prophylaxis, and the
cellular content and source of the graft, may influence
both survival and quality of life. Although the impact of
the first 2 factors has been extensively studied, there are
less data on the optimal doses of graft cellular contents.
Several studies have identified CD341 cell dose as
a critical factor affecting transplantation outcome.449
450 R. Nakamura et al.Higher CD341 cell doses are generally associated with
reduced transplant-related mortality (TRM) and re-
lapse rates and superior survival and disease-free sur-
vival (DFS) rates [1-6]. Similar observations have been
made in HCT using reduced-intensity conditioning
[7,8]. However, the infusion of high doses of CD341
cell has also been associated with an increased rate of
acute and/or chronic GVHD (aGVHD, cGVHD)
[9-11]. Although these studies focused on sibling donor
HCT or matched unrelated donor (MUD) bone mar-
row transplantation, the impact of CD341 cell dose
on outcomes inMUDperipheral blood stem cell trans-
plantation (PBSCT) has not been well characterized.
Granulocyte-colony stimulating factor (G-CSF)-
mobilized PBSCT has been increasingly used in the
MUD transplant setting despite no clear data on sur-
vival advantage or disadvantage. A previous case-con-
trol study showed no difference in GVHD, relapse,
and survival comparing peripheral stem cells to bone
marrowusing unrelated donors, except for an increased
risk for extensive cGVHD with the use of PBSC graft
[12]. Importantly, the impact of CD341 cell dose in
MUD-PBSC transplantations may differ from that
of sibling donor PBSC transplants. In MUD-PBSC
transplantations, the disease risk is generally higher
and immunologic disparity between the recipient and
donor is greater. In addition, inhibitory killer-cell im-
munoglobulin-like receptor ligand (iKIRL) mismatch
in this setting is another factor, which may potentially
influence the risk of relapse [13-16].
In this retrospective study, we sought to determine
whether there was a correlation between the CD341
cell dose of PBSC grafts and clinical outcomes includ-
ing engraftment, survival, disease relapse, and risks of
GVHD following MUD-PBSC transplantation. In
addition, because the higher CD341 cell dose is known
to be associated with faster recovery of NK cells post-
transplant [17], we further investigated the effect of
iKIRL matching combined with CD341 cell dose on
the transplant outcomes.
METHODS
Patients
Between August 2000 and December 2004, a total
of 204 patients with hematologic malignancies under-
went MUD-PBSC transplantation at our institution
under institutional review board-approved protocols.
In this retrospective analysis, we excluded patients
who received a truly nonmyeloablative conditioning
such as low-dose total-body irradiation (TBI) 6 flu-
darabine, because we expected the engraftment kinet-
ics, overall outcome, and relapse risk, would be highly
distinct from the other transplant conditioning regi-
mens. Characteristics of the remaining 181 patients
are shown in Table 1. Of these 181 patients, 35 were
considered to have low-risk disease (acute leukemiaTable 1. Patient and Transplant Characteristics
Number of patients 181
Dates of transplantation August 2000-December 2004
Median follow-up (range) 18 months (range: 3-49)
Median age (range) 44 (1-67)
Sex (F/M) 82/99
Diagnosis
AML 68
ALL 38
NHL/HD 19/4
CML 18
MDS 18
CLL 3
MM 2
Myelofibrosis/MPD 8
Other acute leukemias
(biphenotypic, undifferentiated)
3
Disease risk
Low 35
High 146
Stem cell source
PBSC 181 (100%)
Conditioning regimen
Full intensity (TBI-Cy: 46,
TBI-VP16: 28, Bu-Cy: 9)
83
Reduced intensity (Flu-Mel: 97,
Flu-Bu: 1)
98
GVHD prophylaxis
FK506/MTX 79
CSA (or FK506)/MMF 51
CSA (or FK506)/MMF/MTX 50
FK506/sirolimus 1
Donor/recipient sex combination
female to male 34
Other combinations 147
Donor/recipient CMV serostatus
donor2/recipient1 64
donor1/recipient1 53
donor2/recipient2 38
donor1/recipient2 26
HLA matching
10 of 10 allele match 93
Others (total) (88)
antigen mismatch in A 3
antigen mismatch in C ± DQ 47
antigen mismatch in DQ alone 6
allele mismatch(es) without Ag
mismatch
32
iKIRL matching
iKIRL mismatch
GVH direction 18
HVG direction 11
iKIRL match (or unknown) 149 (3)
Transplant cell doses
median CD341 cells (range) 6.7 (0.6-28) x106/kg
median mononuclear cells (range) 7.1 (5.0-5.06) x1088/kg
median lymphocytes (range) 4.4 (4.0-2.64) x108/kg
AML indicates acutemyelogenous leukemia;ALL, acute lymphoblastic
leukemia; NHL/HD, non-Hodgkin’s lymphoma; HD, Hodgkin’s
disease; CML, chronic myelogenous leukemia; MDS, myelodys-
plastic syndrome;CLL, chronic lymphocytic leukemia;MM,multi-
ple myeloma; MPD, myloproliferative disorders; PBSC, peripheral
blood stemcell;TBI, total-body irradiation;Cy, cyclophosphamide;
VP-16, etoposide; Bu, Busulphan; Flu, fludarabine;Mel,melphalan;
iKIRL, inhibitory killer-cell immunoglobulin-like receptor ligand;
GVH, graft-versus-host; HVG, host-versus-graft.
CD341 Cell Doses and Relapse after MUD-PBSCT 451in first complete remission or chronic myelogenous
leukemia in the chronic phase).
Donors
Unrelated donors were consented and procured
through the National Marrow Donor Program
(NMDP) according to their standards and procedures.
High-resolution polymerase chain reaction sequence-
specific primers (PCR-SSP) for HLA class I and II was
performed using PCR-based DNA sequencing reac-
tions [18]. PBSC donors received a G-CSF at a dose
ranging from 9 to 12.5 mg/kg/day, administered subcu-
taneously once daily for 5 consecutive days. All PBSC
products were unmanipulated.
Criteria of HLA and iKIRL Incompatibility, and
Patients Lacking iKIRLs
HLA compatibility was classified into 2 different
mismatch levels: the antigen level (including split anti-
gens), and the allele level. Ninety-three pairs were 10
of 10 allele level match. In the remaining 88 pairs, an-
tigen mismatch was seen in A (n 5 3), C 6 DQ (n 5
47), or DQ (n 5 6), and allele mismatch(s) without
antigen mismatch was observed in 32 pairs (Table 1).
Killer-cell immunoglobulin-like receptor (KIR)
genotyping was performed with a multiplex PCR-
SSP method [19]. Assignment of iKIRL incompati-
bility in either GVH or host-versus-graft direction
basically followed the previously proposed algorithm
[13,20] (Table 1). Transplants were also analyzed
employing the model of the ‘‘lacking iKIRLs’’ [21]
(Table 1). We also considered the KIR genotyping
results of patients and donors in both models. For
example, in a homozygous HLA-Bw6 patient trans-
planted with a heterozygous HLA-B donor, the
iKIRL mismatch was counted only if the donor geno-
type had KIR3DL1.
Conditioning
As preparative treatment before transplantation,
83 patients received 1 of the full-intensity regimens:
cyclophosphamide (Cy) 60 mg/kg for 2 consecutive
days (n5 46) or etoposide 60 mg/kg for 1 day (n5 28),
combined with TBI in a dose of 1320 cGy over 11
fractions, or busulfan (Bu) 16 mg/kg followed by Cy
60 mg/kg for 2 consecutive days (n5 9). Ninety-eight
patients received reduced-intensity regimens using
fludarabine (Flu) 25 mg/m2 for 5 days and Melphalan
(Mel) 140 mg/m2 (n5 97) or Bu (n5 1). There was no
use of Campath in our regimen, but ATG was used in
3 patients when the risk of graft rejection or GVHD
was considered to be high.
GVHD Prophylaxis
For patients undergoing full-intensity transplant,
GVHD prophylaxis consisted of tacrolimus (FK506)
combined with a short course (4 doses) of methotrex-ate (MTX) at 15 mg/m2 on day 1 and 10 mg/m2 on
days 13, 16, and 111. For reduced-intensity trans-
plants, cyclosporine (CSA) 1.5 mg/kg i.v. twice a day
and mycophenolate mofetil (MMF) at 15 mg/kg i.v.
3 times a day with or without a short course of MTX
at 10 mg/m2 on day 11, then 5 mg/m2 on days 13
and 16 were used.
Supportive Care
Supportive care, including prophylactic antibi-
otics, antifungal therapy, total parenteral nutrition,
hematopoietic growth factors, immune globulin re-
placement, and treatment of mucositis and neutro-
penic fever was administered in accordance with
institutional standard practice guidelines [22]. Moni-
toring for CMV viremia was performed twice a week
from day121 to day1100, using the shell vial method
and/or PCR, and patients received preemptive ganci-
clovir at onset of cytomegalovirus reactivation.
Transplant Cell Doses
Determinations of CD341 cells were performed
on unseparated PBSC by flow cytometry according
to the ISAHGE protocol. Total infused lymphocyte
doses were calculated as follows: (% differential of
the lymphocyte/100  total WBC count of the
PBSC graft)/recipient weight in kg. We did not in-
clude CD31 cell dose in this analysis because the
CD31 count became our standard only recently and
the information was available in a limited number of
patients within this cohort.
Clinical Evaluation
Engraftment. Neutrophil engraftment was de-
fined as the first of 3 consecutive days with an absolute
neutrophil count (ANC) of 0.5 109/Lor above. Plate-
let engraftment was defined as the first of 7 consecutive
days when the platelet count exceeded 20  109/L
without transfusion support.
GVHD. Acute GVHD was graded 0 to IV, accord-
ing to standard criteria [23]. Chronic GVHD was
assessed in patients surviving.90 days after transplan-
tation and defined as limited or extensive [24].
Statistics
Analysis was performed on 181 patients, with ame-
dian follow-up time of 28 months (range: 6.5-59
months) for surviving patients. The probabilities of
overall survival (OS), DFS, relapse, acute and nonre-
lapse mortality (NRM) were calculated with the
Kaplan-Meier method [25], comparing the groups
with use of the log-rank test (Mantel-Haentszel) [26].
We used the Wilcoxon rank-sum test to compare the
means of time to engraftment. In the univariate and
multivariate analyses of risk factors for aGVHD and
prognostic factors for engraftment, the logistic
452 R. Nakamura et al.regression model was used for the binary outcomes
[27]. When analyzing prognostic factors for cGVHD,
TRM, survival, relapse, and DFS, the Cox regression
model was used [28]. Factors significant at the 10%
level in the univariate analysis were entered into the
multivariate analyses. The following factors were ana-
lyzed: total mononucleated cell (MNC) dose, lympho-
cyte dose, CD341 cell dose, disease risk status,
recipient CMV serology, conditioning regimen (full
intensity versus reduced intensity), patient age, and do-
nor/recipient sex (female donor to male recipient ver-
sus other combinations), HLA match status (10 out of
10 match versus others).
RESULTS
Overall Outcomes
Of the 181 patients with a median follow-up of 28
months (range: 6.5-59), 89 patients are alive. The
2-year OS, DFS, relapse, and 100-day TRM probabil-
ities were 52% 6 4%, 47% 6 4%, 29% 6 4%, and
156 3%, respectively. Grade II-IV aGVHD occurred
in 64% of patients (grade 3-4: 30%). Chronic GVHD
was observed in 59% of evaluable patients (52%
extensive).
Characteristics of Infused Products
Median (range) CD341 cell, lymphocyte, and
MNC doses were 6.7 (0.6-28)  106/kg, 4.4 (4.0-
26.4)  108/kg, and 6.9 (5.0-50.6)  108/kg, respec-
tively (Table 1). There was a strong correlation be-
tween Ly and MNC doses (r 5 0.88, P\ .0001), and
less significant correlations between CD341 cell and
Ly (r 5 0.23, P 5 .035) or MNC (r 5 0.24, P 5
.029). For subsequent analysis, the cases were grouped
into 4 categories according to the CD341 cell doses in
quartiles (#percentile 25 [p25]: percentile 25-50 [p25-
50], percentile 50-75 [p50-75], and percentile $75
[p75]). The cutoff values for p25, p50, and p75
were 4.2  106/kg, 6.7  106/kg, and 9.5  106/kg,
respectively.
Impact of Infused CD341 Cell Dose and Transplant
Outcome
Hematopoietic recovery. All patients engrafted
with the median time to ANC .500/mL at 16 days
(range: 7-52) and platelet counts .20,000/mL at 20
days (range: 12-98). There was a significant inverse re-
lationship between higher CD341 cell dose (log scale)
and faster neutrophil engraftment (r520.16,P5 .035,
Figure 1). A similar trendwas observed for engraftment
of platelets without reaching a statistical significance
(r5 20.19, P5 .13).
Time-to-event outcomes. Table 2 shows the re-
sults of univariate Cox analysis for factors associated
with transplant outcomes. Significant prognostic vari-
ables associated with improved OS were 10/10 matchstatus and greater Ly dose (as the continuous variable),
and significant variables for improved DFS included
these 2 factors and low-risk disease status.
ACD341 cell dose 4.2 106/kg (p25) or above was
associated with significantly lower relapse risk (hazard
ratio [HR] 5 0.67; P 5 .013) and a trend for corre-
sponding improvement in DFS (HR 5 0.84; P 5 .12),
but not in OS (HR 5 0.91, P 5 .46). This time-to-
relapse difference was also evident by the Kaplan-
Meier estimates and the log-rank test. At 2 years
posttransplant, CD341 cell dose\4.2  106/kg (q25)
was associated with significantly higher relapse risk
at 44% compared with 24% among patients
with CD341 dose in the upper 3 quartiles (log-rank
P5 .0073; Figure 2a). A trend for better DFS (P5 .11;
Figure 2b) was also noted.However, this was not accom-
panied by an associated improvement in OS (P 5 .45;
Figure 2c). The impact of CD341 cell dose on relapse
was also significant when it was analyzed as a
continuous variable (Table 3).
CD341 cell doses $6.7  106/kg (p50: median)
was associated with reduced relapse risk (HR 5 0.52,
P 5 .042), but this result did not extend to DFS, OS,
or TRM. A CD341 cutoff at 9.5  106/kg (p75) had
no significant impact on OS, DFS, relapse, or TRM.
There was no significant association between the
CD341 cell dose (either as a continuous or categorized
variable) and aGVHD (grade II–IV or III–IV).We ob-
served no significant association between the CD341
dose and cGVHD when the CD341 cell dose was an-
alyzed as a continuous variable (P 5 .19). When the
CD341 dose was categorized in quartiles, CD341
cell dose \ median was associated with increased
cGVHD (P 5 .006, HR 5 0.42; confidence interval
[CI] 0.23-0.78).
In multivariate analysis, cellular composition of
the PBSC grafts remained significant in influencing
transplant outcomes (Table 3), independent of other
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Figure 1. Neutrophil recovery is associated with CD341 cell dose.
There was a significant inverse relationship between higher
CD341 cell dose (log scale) and faster neutrophil engraftment
(r 5 20.16, P 5 .035).
CD341 Cell Doses and Relapse after MUD-PBSCT 453Table 2. Univariate Analysis for Factors Associated with Transplant Outcomes
OS HR (95% CI) DFS HR (95% CI) Relapse HR (95% CI) TRM HR (95% CI)
Age (continuous) 1.00 (0.99-1.01) 1.00 (0.99-1.02) 1.02 (1.00-1.04) 1.01 (0.99-1.02)
P 5 .87 P 5 .48 P 5 .0315 P 5 .47
CD341 dose (continuous) 0.99 (0.95-1.03) 0.98 (0.94-1.01) 0.94 (0.87-1.00) 0.99 (0.94-1.04)
P 5 .60 P 5 .22 P 5 .0533 P 5 .82
CD341 #p25 (baseline) versus .p25 0.91 (0.73-1.17) 0.84 (0.68-1.05) 0.67 (0.49-0.91) 1.01 (0.75-1.41)
P 5 .46 P 5 .12 P 5 .0126 P 5 .94
Ly dose (continuous) 0.41 (0.16-0.96) 0.40 (0.16-0.90) 0.37 (0.09-1.25) 0.48 (0.15-1.28)
P 5 .0396 P 5 .0249 P 5 .12 P 5 .16
Ly #p25 (baseline) versus .p25 0.88 (0.70-1.11) 0.89 (0.72-1.12) 0.93 (0.67-1.35) 0.90 (0.68-1.22)
P 5 .26 P 5 .31 P 5 .70 P 5 .49
MNC dose (continuous) 0.99 (0.61-1.45) 0.88 (0.54-1.28) 0.55 (0.21-1.16) 1.05 (0.59-1.59)
P 5 .95 P 5 .54 P 5 .13 P 5 .86
MNC #p25 (baseline) versus .p25 1.05 (0.84-1.35) 1.01 (0.81-1.28) 0.87 (0.63-1.22) 1.09 (0.81-1.51)
P 5 .67 P 5 .94 P 5 .40 P 5 .59
Disease risk good (baseline) versus
poor risk
1.62 (0.94-3.06) 1.75 (1.03-3.21) 2.03 (0.88-5.91) 1.37 (0.71-2.99)
P 5 .0868 P 5 .0390 P 5 .10 P 5 .37
Sex mismatch: F to M (baseline) versus
other combinations
1.08 (0.83-1.38) 1.07 (0.83-1.35) 1.13 (0.75-1.59) 1.09 (0.77-1.47)
P 5 .55 P 5 .59 P 5 .54 P 5 .61
Full (baseline) versus reduced-intensity
conditioning
1.02 (0.68-1.54) 1.18 (0.80-1.76) 1.34 (0.73-2.53) 0.43 (0.90-2.69)
P 5 .93 P 5 .40 P 5 .35 P 5 .11
Recipient CMV serology
Neg (baseline) versus Pos
1.01 (0.82-1.25) 0.96 (0.78-1.18) 1.0 (0.72-1.37) 0.94 (0.71-1.23)
P 5 .89 P 5 .70 P 5 .98 P 5 .66
10/10 HLAmatch (baseline) versus others 2.11 (1.40-3.26) 1.87 (1.26-2.80) 1.19 (0.64-2.19) 2.25 (1.33-3.93)
P 5 .0004 P 5 .0018 P 5 .57 P 5 .0024
Ly indicates lymphocyte; MNC, mononuclear cell; HR, hazard ratio; OS, overall survival; CI, confidence interval’ MNC: mononuclear cell;
CMV, cytomegalovirus; DFS, disease-free survival; TRM, transplant-related mortality.variables such as conditioning regimen or disease risk
status. Similar to the univariate analysis, the greater
lymphocyte dose (as the continuous variable) was asso-
ciated with improved OS and DFS. A greater CD341
cell dose $p25 was associated with reduced relapse
without improved OS or DFS independent of disease
risk status or conditioning regimens (reduced intensity
or full intensity). Total MNC dose infused also af-
fected OS when grouped as \p25 versus $p25, in
which the higher MNC dose was associated with infe-
rior survival. As expected, patients who received trans-
plant from a 10/10 matched donor had a significantly
better OS and DFS associated with reduced TRM.
We found that the increased patient age was associated
with slightly higher risk (HR 5 1.02, P 5 .03) of re-
lapse in our cohort. We observed that reduced-inten-
sity conditioning (RIC) was associated with increased
TRM, likely because of underlying comorbidities
such as age, organ function, and performance status.
Association between CD341 Cell Dose and
Posttransplant Lymphocyte Recovery
We evaluated a possibility that the protective effect
of CD341 cell dose on relapse may be immune medi-
ated.We found a highly significant correlation between
CD341 cell dose infused and absolute lymphocyte
count (ALC) on day 30 posttransplant (r 5 0.378,
P \ .0001; Figure 3), suggesting that the higher
CD341 cell dose contributes to faster lymphoid recov-
ery. The relationship between infused NMC and ALCwas less significant (P5 .027). There was no significant
association between infused lymphocyte dose and ALC
(P5 .1).
Subset Analysis: The CD341 Dose Effect Is
Observed in Myeloid Cancers, RIC, High-Risk
Diseases, Patients with an iKIRL Mismatch in the
GVH Direction, and Those Who Lack iKIRL
It has been known that NK cells largely contribute
to the ALC recovery early posttransplant [29]. Because
we observed a close relationship between infused
CD341 cell dose and faster ALC recovery, we hypoth-
esized that the protective effect against relapse in the
higher CD341 cell dose may be linked to an NK cell-
mediated graft-versus-leukemia(GVL)/lymphoma ef-
fect. In this retrospective study, we had no saved blood
samples that we could directly analyze NK cell num-
bers and functions. Instead, we evaluated the CD341
cell dose effect in the following subsets of patients: (1)
myeloid cancers versus lymphoid cancers, (2) RIC ver-
sus full-intensity conditioning, (3) donor-recipient
pairs with iKIRL mismatch in the GVH direction ver-
sus the pairs without iKIRL mismatch in the GVH di-
rection, and (4) patients lacking iKIRL.We expected to
see an enhanced CD341 cell dose effect in myeloid pa-
tients, pairs with KIRmismatch in the GVH direction,
and patients lacking iKIRL.
In a subgroup of 104 myeloid cancer patients
(AML,CML, andmyelodysplastic syndromes [MDS]),
there were no statistically significant differences
454 R. Nakamura et al.between the upper 3 quartiles of CD341 cell dose
versus the lowest quartile with respect to OS or
DFS. However, the log-rank P-value for comparing
time to relapse in the myeloid subgroup was P 5
.0567 (Figure 4). Among the 64 patients in the lym-
phoid malignancy subgroup (ALL, NHL, HD, and
CLL), there were no statistically significant differ-
ences with respect to any time-to-event endpoints
when we compared the lowest quartile of CD341
cell dose versus the upper 3 quartiles.
We also analyzed the impact of CD341 cell dose
separately in RIC (n 5 98) and full-intensity condi-
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Figure 2.EffectofCD341 celldoseon relapse (a),DFS(b), andOS(c).tioning (n 5 83). The log-rank P-value for comparing
time to relapse between the upper 3 quartiles of
CD341 cell dose versus the lowest quartile in the
reduced-intensity subgroup was P5 .0192 (47.6% ver-
sus 24.7%), whereas it was not significant in the full-
intensity subgroup. In the reduced-intensity subgroup,
however, there was no corresponding significant
improvement in OS or DFS with higher CD341
cell doses.
There were 18 patients with an iKIRLmismatch in
the GVH direction. Among this subgroup, the log-
rank P-value for comparing the lowest quartile (p25)
of CD341 cell dose versus those who received higher
doses was P\ .0001 with respect to time to relapse.
This is in contrast with a log-rank P-value of P 5
.041 among those patients who did not have an iKIRL
mismatch in the GVH direction. Whereas the CD341
cell dose in patients without iKIRL mismatch showed
no statistically significant difference in DFS, the log-
rank P-value for DFS was significant in those with
a iKIRL mismatch in the GVH direction (P 5 .0053).
iKIRL mismatch stratified by CD341 cell dose was
not statistically significant on OS.
We also performed a stratified analysis in patients
lacking iKIRL versus not. There were 125 patients
lacking iKIRL and 56 without lacking iKIRL. When
stratified by CD341 cell dose, time to relapse was
not significant among the patients who did not lack
iKIRL but was significant in patients lacking iKIRL
(log-rank P 5 .0030). The impact of the higher dose
Table 3. Significant Factors Associated with OS, DFS, Relapse, and TRM
by Multivariate Analysis (Cox Regression)
OS HR P-values
10/10HLAmatch (baseline)
versus others
2.23 (95%CI 1.46-3.43) .0002
Lymphocyte dose in the
graft (continuous)
0.20 (95%CI 0.05-0.64) .0045
MNC dose in the graft: p25
(baseline) versus others
1.34 (95%CI 1.01-1.82) .0388
DFS
10/10HLAmatch (baseline)
versus others
1.91 (95%CI 1.28-2.87) .0014
Lymphocyte dose in the
graft (continuous)
0.35 (95%CI 0.14-0.81) .0123
Good risk disease (baseline)
versus others
1.73 (95%CI 1.01-3.17) .044
Relapse
CD341 quartile: p25
(baseline) versus others
0.64 (95%CI 0.47-0.88) .0077
Recipient age (continuous) 1.02 (95%CI 1.00-1.05) .019
TRM
10/10HLAmatch (baseline)
versus others
2.46 (95%CI 1.44-4.30) .0009
Full-intensity (baseline)
versus reduced-intensity
conditioning
1.76 (95%CI 1.03-3.10) .038
MNC: mononuclear cell; see Tables 1 and 2 for other abbreviations.
CD341 Cell Doses and Relapse after MUD-PBSCT 455of CD341 cells in patients lacking iKIRL did not ex-
tend to improved DFS or OS, however.
Further subset analysis of the standard-risk group
(n 5 35; Table 1) versus high-risk disease (n 5 146)
showed that the CD341 dose $p25 was significantly
associated with reduced relapse in high-risk disease
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Figure 3. Absolute lymphocyte count on day 130 posttransplant is
associated with CD341 cell dose. There was a highly significant cor-
relation between CD341 cell dose infused and ALC on day 30 post-
transplant (r 5 0.378, P\ .0001).
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Figure 4.Effect of CD341 cell dose on relapse inmyeloid cancers (a)
and lymphoid cancers (b).(P 5 .015), whereas the P-value was not significant in
low-risk disease (P 5 .5).
DISCUSSION
There have been several studies demonstrating the
impact of CD341 cell dose on transplant outcomes
[1-6]. However, the data are limited to sibling donor
transplants or unrelated donor bone marrow trans-
plant. In ourMUD-PBSC cohort, we observed a faster
neutrophil and platelet recovery with higher CD341
cell dose, which is consistent with the earlier reports.
Importantly, we found that patients who received
higher numbers of CD341 cells had a lower relapse
rate. Subset analysis suggests that this may bemore im-
portant inmyeloid diseases that are typically associated
with a stronger GVL effect. In addition, the beneficial
effect of a higher CD341 cell dose in reducing relapse
was more evident in high-risk diseases than in low-risk
diseases, consistent with an earlier study [8].
In our cohort, the significance of the CD341 cell
dose was highest when the group was separated by
the CD341 cell dose at the lowest quartile (p25) versus
the others (cutoff: 4.2 106/kg) rather than by median
or at p75. It is thus possible that the CD341 cell dose
level above which there is no further benefit for reduc-
ing relapse may lie around the dose of 4-5  106/kg.
The protective effect of a higher CD341 cell dose
for relapse resulted in a trend for improved DFS but
did not translate to a better OS. Although we observed
no significant difference in TRM or aGVHD accord-
ing to the CD341 cell dose, there is a possibility that
the higher CD341 cell dose may negatively impact
on TRMwithout reaching a statistical significance be-
cause of the size of this study. Contrary to a few previ-
ously published studies in sibling donor PBSCT
[10,11], we observed a reduced risk of cGVHD when
higher CD341 cell doses were infused.
The mechanism in which the higher CD341 dose
reduces relapse is not known. One possible mechanism
is that the higher CD341 cell dose may improve im-
mune recovery, which induces a stronger GVL effect.
In the early posttransplant period, the majority of pe-
ripheral blood lymphocytes are NK cells [30], which
can mediate cytotoxicity without prior sensitization
and may be responsible for early GVL effects [31]. A
study by Savani et al. [17] showed that higher
CD341 doses established an earlier donor NK cell
population, resulting in superior antileukemic activity
posttransplant [17]. In agreement with that work, we
found a significant association between CD341 cell
dose and early lymphocyte recovery. The possibility
of NK cell-mediated GVL is further suggested by
the findings that the higher CD341 cell dose was asso-
ciated with (1) greater reduction in relapse in myeloid
malignancies compared to lymphoid malignancies, (2)
greater reduction in relapse when there is an iKIRL
456 R. Nakamura et al.mismatch in theGVHdirection, and (3) greater reduc-
tion in relapse when there is a lack of iKIRL. Our sub-
set analysis on reduced-intensity transplants was also
consistent with a possility that the CD341 cell dose
may be more important in reduced-intensity trans-
plants as they likely rely more on GVL.
Allospecific interactions between donor NK cells
and recipient leukemic cells was originally demon-
strated in the clinical setting of T cell-depleted HCT
from MHC haplotype–disparate related donors [13].
The pivotal structural elements underlying this mech-
anism are KIR, which are clonally expressed on the
surface of NK cells or certain T cell subsets, and mem-
brane-bound MHC class I molecules as their natural
ligands on target cells [31-33]. Because our study was
limited to retrospective analysis, it was not possible
to demonstrate correlative in vitro data for NK-medi-
ated GVL. A prospective study of evaluating NK cell
recovery and function posttransplant is currently un-
derway in our institution.
Our data need to be interpreted with caution. Con-
founding factors in our study include various regimens
for GVHD prophylaxis and conditioning, various de-
grees of HLA matching, as well as combining patients
with heterogeneous diagnoses, although multivariate
analysis showed an independent effect of CD341 doses.
We cannot definitively differentiate the effect of higher
Ly dose resulting in greater GVL versus a GVL effect
fromahigherCD341dose. In this study, therewasacor-
relationbetween theCD341 dose and theLydose in the
PBSC grafts. Lymphocyte recovery after allogeneic
PBSCT can be affected not only by CD341 cells but
also by lymphocyte content of the graft [34]. However,
higher lymphocyte dose in our study was associated
with betterOS andDFS but not with decreased relapse,
suggesting that the GVL effect was more closely linked
to the CD341 cell dose than Ly dose.Multivariate anal-
ysis also indicated the effect of higher CD341 cell doses
in reducing relapse was independent of the Ly dose.
It should also be noted that the graft cell dose
(CD341 cell, Ly) may not necessarily be the prime de-
terminant of leukemia relapse. These parameters may
be surrogates for other measures of T cell and NK cell
function, antigen-presenting cells, engraftment, or
pathologic processes that ultimately result in relapse
of residual disease.
In summary, we demonstrate that the graft cell
dose affects transplant outcome in MUD-PBSCT,
and that higher CD341 cell doses reduce relapse rates,
in particular, for high-risk diseases. The data also sug-
gest that the protective effect of higher CD341 cell
dose may be immune-mediated, possibly through
NK cell recovery. Further detailed characterization
of the graft content and functional assessment of
emergingNK cells posttransplant are necessary to bet-
ter understand the mechanism, and to improve out-
comes after MUD-PBSCT.ACKNOWLEDGMENTS
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